AZN

AstraZeneca (LSE:AZN) received US FDA approval for IMFINZI (durvalumab) with BCG therapy in BCG naïve, high risk non muscle invasive bladder cancer, based on positive Phase III data showing a significant reduction in disease recurrence. The IMFINZI decision marks a new bladder cancer indication for the company in a patient group with high unmet medical needs. The company also reported recent regulatory milestones for Datroway and Enhertu in major global markets, adding to its oncology...

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and

Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug Wainua, expected in the third quarter of 2026. Wainua is a TTR-silencer, a drug that suppresses production of a protein called...

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.

Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally.

Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase. Read more on IONS stock here.

Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.

US equity futures were edging lower pre-bell Thursday as fresh US and Iranian strikes once again thr

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder

Sellas believes GPS-treated AML patients could live longer than those receiving standard treatment, with a projected survival of about 12.6 months versus 8 months.

ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively. See why AZN stock is a strong buy.

Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistryEnhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or met

EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver cancerPhase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 spanEMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver cancer

The abrdn Global Dynamic Dividend Fund offers an 11.52% yield by investing primarily in global equities, focusing on dividend income. Read more on AGD CEF here.

Tectonic Therapeutics (TECX) and TX45 for PH-HFpEF: Phase 1b results, risks, and the pivotal Phase 2 APEX catalyst due YE26—read the analysis now.